Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

By Bailey B.  

Irish Journal of Medical Science, Vol. 180, Iss. 2, 2011-06 ,pp. : 337-341

Springer Publishing Company

Access to resources Recommend Favorite

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs*

By Birnbaum Howard G.   Ivanova Jasmina I.   Samuels Seth   Davis Matthew   Cremieux Pierre Y.   Phillips Amy L.   Meletiche Dennis  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 869-877

Informa Healthcare

Access to resources Recommend Favorite

Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment

By Lage Maureen J.   Carroll Cathryn A.   Fairman Kathleen A.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1146-1153

Informa Healthcare

Access to resources Recommend Favorite

Medication Persistence of Disease‐Modifying Antirheumatic Drugs and Anti–Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil

By  

ARTHRITIS CARE AND RESEARCH, Vol. 68, Iss. 10, 2016-10 ,pp. : 1489-1496

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population

By Kamat Siddhesh A.   Bullano Michael F.   Chang Chun-Lan   Gandhi Sanjay K.   Cziraky Mark J.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 961-968

Informa Healthcare

Access to resources Recommend Favorite